| Name | Title | Contact Details |
|---|---|---|
Chandra Pydi |
Vice President, IT Portfolio Management | Profile |
Chris Walzer |
Vice President & CIO, SPMR | Profile |
Kallie Smith |
Director, Cyber Security at McKesson | Profile |
Tiffany Chisum |
Director of Information Security | Profile |
Olanrewaju Oluleye |
Senior Manager, Cyber Fraud Defense | Profile |
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
DMD Pharmaceuticals is a Noblesville, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cedarburg Pharmaceuticals delivers unsurpassed value in the development and manufacturing of commercial and clinical APIs. We believe value is more than just price. Value means making your life simpler. Our process development, scale-up, commercial
LifeWays is the Community Mental Health Agency for Jackson and Hillsdale Counties. We provide specialty mental health services to individuals with Medicaid or Healthy Michigan, living in Jackson or Hillsdale County. Once someone receives a screenin...
ARTMS Inc. is the global leader in the development of novel technologies and products for enabling the cyclotron production of the world’s most-used diagnostic imaging isotopes.